drugset / Trial / NCT00002866

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

NCT00002866

Phase 1 Completed 50 enrolled NCIC Clinical Trials Group
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person 's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of docetaxel and epirubicin with and without G-CSF in treating women with metastatic breast cancer.

Timeline

Start
1996-08-12
Primary completion
2005-07-19
Completion
2009-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject Epirubicin Small molecule Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous